New Studies Examine the Use of Liquid Biopsies and the Possible Causes of Myeloma

Two newly published studies that received funding from the IMF Black Swan Research Initiative® show how myeloma might be diagnosed and monitored in the future, and, perhaps, the genetic factors that might cause the disease. In his blog this week, IMF Chairman Dr. Brian Durie translates the studies’ implications and offers important caveats for patients to keep in mind. 

 

Is MRD testing ready for “prime time”?

The answer is a definite yes and no! Yes, it is now a priority to test for minimal residual disease (MRD) in myeloma clinical trials. However, no, MRD testing is not yet recommended in routine clinical practice.  But I’m pleased to report that we are getting there.